http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-103720719-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-15 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-02 |
| filingDate | 2013-10-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2016-07-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2016-07-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-103720719-B |
| titleOfInvention | The technology of one DC and Treg cell therapy lupus erythematosus |
| abstract | The technology of one DC and Treg cell therapy lupus erythematosus, comprises the following steps: (1) gathers peripheric venous blood from the non-period of disease of patients with SLE；(2) by density gradient separation, separate from blood and obtain mononuclearcell；(3) being poured into by supernatant in new culture vessel after mononuclearcell culture fluid being cultivated 2h in culture vessel, in former culture vessel, attached cell is used for being divided into DC, and the suspension cell in new container is divided into Treg cell；(4) in the culture fluid of DC differentiation, add specific antigen, carry out DC functionalization；(5) DC and Treg cell co-cultivation amplification；(6) the cell normal saline after amplification cleans laggard row vein instillation adoptive therapy lupus erythematosus.The present invention recovers immune system normal condition by cellular immunization technology, and DC and Treg cell belongs to human body cell, can be long-time resident internal in vivo, reaches long-term treatment effects. |
| priorityDate | 2013-10-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 81.